Jump to content

FICD

Add links
From Wikipedia, the free encyclopedia
(Redirected from Draft:FICD)

FIC domain protein adenylyltransferase (FICD) is an enzyme in metazoans possessing adenylylation and deadenylylation activity (also known as (de)AMPylation), and is a member of the Fic (filamentation induced by cAMP) domain family of proteins. AMPylation is a reversible post-translational modification that FICD performs on target cellular protein substrates. FICD is the only known Fic domain encoded by the metazoan genome, and is located on chromosome 12 in humans.[1] Catalytic activity is reliant on the enzyme's Fic domain, which catalyzes the addition of an AMP (adenylyl group) moiety to the substrate. FICD has been linked to many cellular pathways, most notably the ATF6 and PERK branches of the UPR (unfolded protein response) pathway regulating ER homeostasis.[2] FICD is present at very low basal levels in most cell types in humans,[3] and its expression is highly regulated. Examples of FICD include HYPE (Huntingtin Yeast Interacting Partner E) in humans, Fic-1 in C. elegans, and dfic in D. melanogaster.[4]

Structure

[edit]

The structure of FICD proteins consists of different regions, which are the SS/TM (signal sequence/transmembrane domain),TPR (tetratricopeptide repeat) domain and fic (filamentation induced by cAMP) domain. The secondary structure is primarily composed of nine α-helices. All FICD proteins share the same catalytic motif in their fic domain, consisting of the amino acid sequence HxFx(D/E)(G/A)N(G/K)R1xxR2, located at the C terminus of the protein.[5][6] At the N terminus of the protein is an inhibitory α-helix, composed of the motif (S/T)xxxE(G/N).[7] Interaction between the glutamate of the inhibitory α-helix and the second arginine of the fic motif prevent ATP from entering the catalytic cleft of the protein and participating in AMPylation. This auto-inhibition leads to very low activity of FICD proteins in vitro.[7]

Mutants of FICD have been created which lead to different activity levels in vitro. A mutation of the catalytic histidine in the fic motif to an alanine leads to a complete loss of AMPylation activity by the enzyme.[8] Conversely, mutation of the glutamate in the inhibitory α-helix to a glycine abolishes any auto-inhibition, creating a constitutively active enzyme.[7][9][2]

FICD proteins can exist as either a dimer or a monomer, although they generally exist as an asymmetric dimer in solution. Linkage occurs between the fic domains of the two monomers to form the dimer.[6] New crystal structures have recently been published to model the structure the HYPE monomer.[6][10][11][12]

Mechanism

[edit]

FICD's AMPylation activity is dependent on the sequence of its fic motif (HxFx(D/E)(G/A)N(G/K)R1xxR2). The basic mechanism of AMPylation involves the addition of an AMP group to a substrate residue containing a hydroxyl group, where the AMP group is taken from an ATP molecule. In the case of FICD proteins, the catalytic histidine acts as a general base, drawing a proton away from the hydroxyl group of the substrate (usually located on a threonine or serine residue). The hydroxyl group, now a nucleophile, will then attack the α-phosphate of ATP, thus attaching the AMP group to the target residue's hydroxyl group. This mechanism both requires the presence of the catalytic histidine and the correct orientation of ATP in the ATP-binding pocket of the FICD protein. Interactions between the secondary arginine (HxFx(D/E)GN(G/K)R1xxR2) and the γ-phosphate of ATP orients ATP correctly in the pocket so that the proton transfer between the hydroxyl group of the substrate and the α-phosphate of ATP can take place.[13]

One mechanism by which FICD proteins are self-regulated is through interactions of the inhibitory α-helix and the catalytic fic domain. The glutamate found in the inhibitory α-helix motif ((S/T)xxxE(G/N))interacts with the secondary arginine in the fic motif, which in turn prevents interactions of the γ-phosphate of ATP at that site. Because ATP is unable to orient properly in the ATP binding pocket, AMPylation cannot occur.[7]

FICD proteins are also capable of de-AMPylation activity, the complement to AMPylation. Research suggests that a switch between the dimerization state of FICD may be responsible for the switch between AMPylation and de-AMPylation activity, in which FICD in its monomeric form is responsible for AMPylation, while FICD as a dimer is responsible for de-AMPylation.[14][15]

Function

[edit]

FIC proteins are known for their general function of carrying out post-translational modifications on target proteins that are a part of the cell signaling system. The conserved fic domain is involved in the addition of phosphate-containing compounds including AMP,GTP and other nucleoside monophosphates and phosphates. Fic proteins play a vital role in the mediation of post-translational modifications in host cell proteins that interfere with cytoskeletal, trafficking, signaling or translation pathways such as the UPR pathway. The UPR (unfolded protein response) pathway depends on the activation of transmembrane transducers during ER stress to promote specific downstream effects. In the event of fluctuating unfolded proteins the UPR pathway becomes activated, and this includes the activation of Hsp70 chaperone, Bip. This process incorporates inactive oligomers and reversible AMPylation and de-AMPylation activities. Bip/GRP78 is adenylated by HYPE, which induces the UPR activation, reportedly at the specific sites Thr366 and Thr518 in vitro, and thereby is able to assist in carrying out the modifications to target proteins in order to maintain ER homeostasis. The expression of HYPE is regulated depending on the magnitude of ER stress.[16]

Expression

[edit]

Expression of FICD in most species and cell types occurs at very low levels, with human FICD (HYPE) being expressed between 2-20 NX of RNA in human cell lines.[1] In humans, HYPE's under-expression has been linked to decreased ability of the UPR to maintain ER homeostasis.[2]

In Drosophilia, knockdown of FICD (dfic in D. melanogaster) causes blindness in flies. This phenotype could be rescued by the expression of wild-type dfic in the glial cells of those flies.[17]

In C. elegans, FICD (FIC-1 in C. elegans) is also expressed at a basal level throughout all cell types in the worm body. FIC-1 also shows no change in level of expression throughout the worm's lifetime. FIC-1 expression has been linked to immunity to P. aeruginosa, as mutants with inactive FIC-1 showed increased susceptibility to the bacteria.[5]

Localization

[edit]

The region of localization depends on the type of organism that different FIC proteins reside in. In many cases FICD is situated in the lumen of the endoplasmic reticulum where it adenylates Hsp70 chaperone, binding immunoglobulin protein (BiP) at the Thr-366 and Thr-518. HYPE localizes in the ER via its hydrophobic N-terminus. Drosophila CG9523 or dFic  can be found in the cytosolic region but are also transcriptionally activated during ER stress.

HYPE has two sites of N- glycosylation at Asn275 and Asn446. FICD is a type II transmembrane protein with the Fic domain facing the ER lumen.[18] Similar results have been shown for dFic through in vitro translation in the presence of microsomes, which indicated N-glycosylation at site Asn288.[17]

Clinical Significance

[edit]

While FICD (HYPE in humans) has not been directly linked to any disease pathways, some of its substrates are known participants in human diseases. BiP (GRP78/HSPA5), a validated substrate of HYPE,[2] has been substantially linked to increased rates of cancer cell survival under proapoptotic conditions.[19] α-syn, a putative substrate for HYPE, is a known factor in the development of Parkinson's disease through the formation of protein aggregates in the brain.[20][21] HYPE also has other potential roles in the fields of neurodevelopment and neurodegeneration.[22]

References

[edit]
  1. ^ a b "UniProtKB - Q9BVA6 (FICD_HUMAN)". Uniprot.
  2. ^ a b c d Sanyal, Anwesha; Chen, Andy J.; Nakayasu, Ernesto S.; Lazar, Cheri S.; Zbornik, Erica A.; Worby, Carolyn A.; Koller, Antonius; Mattoo, Seema (2015-03-27). "A Novel Link between Fic (Filamentation Induced by cAMP)-mediated Adenylylation/AMPylation and the Unfolded Protein Response". Journal of Biological Chemistry. 290 (13): 8482–8499. doi:10.1074/jbc.M114.618348. ISSN 0021-9258. PMC 4375499. PMID 25601083.
  3. ^ "Cell atlas - FICD - The Human Protein Atlas". www.proteinatlas.org. Retrieved 2020-08-31.
  4. ^ Truttmann, Matthias C.; Ploegh, Hidde L. (August 2017). "rAMPing Up Stress Signaling: Protein AMPylation in Metazoans". Trends in Cell Biology. 27 (8): 608–620. doi:10.1016/j.tcb.2017.03.004. PMC 5524611. PMID 28433487.
  5. ^ a b Truttmann, Matthias C.; Cruz, Victor E.; Guo, Xuanzong; Engert, Christoph; Schwartz, Thomas U.; Ploegh, Hidde L. (2016-05-03). Tan, Man-Wah (ed.). "The Caenorhabditis elegans Protein FIC-1 Is an AMPylase That Covalently Modifies Heat-Shock 70 Family Proteins, Translation Elongation Factors and Histones". PLOS Genetics. 12 (5): e1006023. doi:10.1371/journal.pgen.1006023. ISSN 1553-7404. PMC 4854385. PMID 27138431.
  6. ^ a b c Bunney, Tom D.; Cole, Ambrose R.; Broncel, Malgorzata; Esposito, Diego; Tate, Edward W.; Katan, Matilda (2014-12-02). "Crystal Structure of the Human, FIC-Domain Containing Protein HYPE and Implications for Its Functions". Structure. 22 (12): 1831–1843. doi:10.1016/j.str.2014.10.007. ISSN 0969-2126. PMC 4342408. PMID 25435325.
  7. ^ a b c d Engel, Philipp; Goepfert, Arnaud; Stanger, Frédéric V.; Harms, Alexander; Schmidt, Alexander; Schirmer, Tilman; Dehio, Christoph (February 2012). "Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins". Nature. 482 (7383): 107–110. Bibcode:2012Natur.482..107E. doi:10.1038/nature10729. ISSN 0028-0836. PMID 22266942. S2CID 4414158.
  8. ^ Worby, Carolyn A.; Mattoo, Seema; Kruger, Robert P.; Corbeil, Lynette B.; Koller, Antonius; Mendez, Juan C.; Zekarias, Bereket; Lazar, Cheri; Dixon, Jack E. (2009-04-10). "The Fic Domain: Regulation of Cell Signaling by Adenylylation". Molecular Cell. 34 (1): 93–103. doi:10.1016/j.molcel.2009.03.008. ISSN 1097-2765. PMC 2820730. PMID 19362538.
  9. ^ Goepfert, Arnaud; Stanger, Frédéric V.; Dehio, Christoph; Schirmer, Tilman (2013-05-30). "Conserved Inhibitory Mechanism and Competent ATP Binding Mode for Adenylyltransferases with Fic Fold". PLOS ONE. 8 (5): e64901. Bibcode:2013PLoSO...864901G. doi:10.1371/journal.pone.0064901. ISSN 1932-6203. PMC 3667792. PMID 23738009.
  10. ^ Perera, Luke A.; Preissler, Steffen; Zaccai, Nathan R; Prévost, Sylvain; Devos, Juliette M; Haertlein, Michael; Ron, David (2021-04-20). "Structures of a deAMPylation complex rationalise the switch between antagonistic catalytic activities of FICD (14/96/109)". doi:10.1101/2021.04.20.440599. S2CID 233415924. {{cite journal}}: Cite journal requires |journal= (help)
  11. ^ Fauser, Joel; Gulen, Burak; Pogenberg, Vivian; Pett, Christian; Pourjafar-Dehkordi, Danial; Krisp, Christoph; Höpfner, Dorothea; König, Gesa; Schlüter, Hartmut; Feige, Matthias J.; Zacharias, Martin (December 2021). "Specificity of AMPylation of the human chaperone BiP is mediated by TPR motifs of FICD". Nature Communications. 12 (1): 2426. Bibcode:2021NatCo..12.2426F. doi:10.1038/s41467-021-22596-0. ISSN 2041-1723. PMC 8065156. PMID 33893288.
  12. ^ Sanyal, Anwesha; Zbornik, Erica A.; Watson, Ben G.; Christoffer, Charles; Ma, Jia; Kihara, Daisuke; Mattoo, Seema (2021-05-03). "Kinetic and structural parameters governing Fic-mediated adenylylation/AMPylation of the Hsp70 chaperone, BiP/GRP78". Cell Stress and Chaperones. 26 (4): 639–656. doi:10.1007/s12192-021-01208-2. ISSN 1355-8145. PMC 8275707. PMID 33942205.
  13. ^ Xiao, Junyu; Worby, Carolyn A; Mattoo, Seema; Sankaran, Banumathi; Dixon, Jack E (August 2010). "Structural basis of Fic-mediated adenylylation". Nature Structural & Molecular Biology. 17 (8): 1004–1010. doi:10.1038/nsmb.1867. ISSN 1545-9993. PMC 2920259. PMID 20622875.
  14. ^ Casey, Amanda K.; Moehlman, Andrew T.; Zhang, Junmei; Servage, Kelly A.; Krämer, Helmut; Orth, Kim (2017-12-22). "Fic-mediated deAMPylation is not dependent on homodimerization and rescues toxic AMPylation in flies". Journal of Biological Chemistry. 292 (51): 21193–21204. doi:10.1074/jbc.M117.799296. ISSN 0021-9258. PMC 5743091. PMID 29089387.
  15. ^ Perera, Luke A; Rato, Claudia; Yan, Yahui; Neidhardt, Lisa; McLaughlin, Stephen H; Read, Randy J; Preissler, Steffen; Ron, David (2019-11-04). "An oligomeric state-dependent switch in the ER enzyme FICD regulates AMPylation and deAMPylation of BiP". The EMBO Journal. 38 (21): e102177. doi:10.15252/embj.2019102177. ISSN 0261-4189. PMC 6826200. PMID 31531998.
  16. ^ Veyron, Simon; Peyroche, Gérald; Cherfils, Jacqueline (2018-03-01). "FIC proteins: from bacteria to humans and back again". Pathogens and Disease. 76 (2). doi:10.1093/femspd/fty012. PMID 29617857.
  17. ^ a b Rahman, Mokhlasur; Ham, Hyeilin; Liu, Xinran; Sugiura, Yoshie; Orth, Kim; Krämer, Helmut (June 2012). "Visual neurotransmission in Drosophila requires expression of Fic in glial capitate projections". Nature Neuroscience. 15 (6): 871–875. doi:10.1038/nn.3102. ISSN 1097-6256. PMC 3578554. PMID 22544313.
  18. ^ Mattoo, Seema; Sengupta, Ranjan (2018). "The subcellular distribution of the human Fic protein, HYPE/FicD, using a high resolution, tomography compatible electron microscopic method". The FASEB Journal. 32 (S1): 526.17. doi:10.1096/fasebj.2018.32.1_supplement.526.17. ISSN 1530-6860. S2CID 249779474.
  19. ^ Wang, Miao; Wey, Shiuan; Zhang, Yi; Ye, Risheng; Lee, Amy S. (September 2009). "Role of the Unfolded Protein Response Regulator GRP78/BiP in Development, Cancer, and Neurological Disorders". Antioxidants & Redox Signaling. 11 (9): 2307–2316. doi:10.1089/ars.2009.2485. ISSN 1523-0864. PMC 2819800. PMID 19309259.
  20. ^ Sanyal, Anwesha; Dutta, Sayan; Camara, Ali; Chandran, Aswathy; Koller, Antonius; Watson, Ben G.; Sengupta, Ranjan; Ysselstein, Daniel; Montenegro, Paola; Cannon, Jason; Rochet, Jean-Christophe (2019-05-31). "Alpha-Synuclein Is a Target of Fic-Mediated Adenylylation/AMPylation: Possible Implications for Parkinson's Disease". Journal of Molecular Biology. 431 (12): 2266–2282. doi:10.1016/j.jmb.2019.04.026. ISSN 0022-2836. PMC 6554060. PMID 31034889.
  21. ^ Spillantini, Maria Grazia; Schmidt, Marie Luise; Lee, Virginia M.-Y.; Trojanowski, John Q.; Jakes, Ross; Goedert, Michel (August 1997). "α-Synuclein in Lewy bodies". Nature. 388 (6645): 839–840. Bibcode:1997Natur.388..839G. doi:10.1038/42166. ISSN 1476-4687. PMID 9278044. S2CID 4419837.
  22. ^ Sieber, Stephan A.; Cappello, Silvia; Kielkowski, Pavel (2020-07-16). "From Young to Old: AMPylation Hits the Brain". Cell Chemical Biology. 27 (7): 773–779. doi:10.1016/j.chembiol.2020.05.009. ISSN 2451-9456. PMID 32521229. S2CID 219593179.
Retrieved from "https://wiki.riteme.site/w/index.php?title=FICD&oldid=1220878165"